Mackenzie Financial Corp Has $2.03 Million Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Mackenzie Financial Corp boosted its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 423.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 117,387 shares of the company's stock after acquiring an additional 94,978 shares during the quarter. Mackenzie Financial Corp owned 0.14% of Progyny worth $2,025,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PGNY. Barclays PLC boosted its position in Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after buying an additional 594,140 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after purchasing an additional 1,526 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in Progyny during the 4th quarter valued at approximately $1,124,000. KBC Group NV increased its holdings in Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after purchasing an additional 2,140 shares during the last quarter. Finally, Guidance Capital Inc. purchased a new stake in Progyny during the 4th quarter worth approximately $380,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Price Performance

NASDAQ PGNY traded down $0.68 on Wednesday, hitting $21.30. 1,102,378 shares of the stock were exchanged, compared to its average volume of 1,706,975. The company's 50-day moving average price is $22.07 and its two-hundred day moving average price is $20.24. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $30.42. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 36.72, a P/E/G ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $324.04 million during the quarter, compared to analysts' expectations of $307.86 million. During the same period in the prior year, the company posted $0.17 earnings per share. The firm's revenue was up 16.5% on a year-over-year basis. Equities analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analysts Set New Price Targets

PGNY has been the topic of a number of recent analyst reports. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Bank of America lifted their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group dropped their target price on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Progyny has a consensus rating of "Hold" and an average target price of $23.45.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.